Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Natalia Sergina, Mark M. Moasser, Megan Rausch et al.|Nature|2007Cited by 991
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinasesBeth Apsel, Zachary A. Knight, Randy Hoffman et al.|Nature Chemical Biology|2008Cited by 440
Structure-guided development of affinity probes for tyrosine kinases using chemical geneticsJimmy A. Blair, Kevan M. Shokat, Daniel Rauh et al.|Nature Chemical Biology|2007Cited by 203
Resiliency and Vulnerability in the HER2-HER3 Tumorigenic DriverDhara N. Amin, Mark M. Moasser, Natalia Sergina et al.|Science Translational Medicine|2010Cited by 185
Kinetics of Inhibitor Cycling Underlie Therapeutic Disparities between EGFR-Driven Lung and Brain CancersKrister J. Barkovich, William A. Weiss, Sujatmi Hariono et al.|Cancer Discovery|2012Cited by 55